Records containing: Triple Negative Breast Cancer
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2019-07-18A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and Hepatocellular Carcinoma
-
CLINICAL_TRIALS study record update · 2019-04-26A Phase II Trial Evaluating Safety and Efficacy of Pembrolizumab and Cisplatin in Patients With Advanced Triple Negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2019-03-21Randomized Phase Ⅲ Trial Comparing Dose-dense Epirubicin and Cyclophosphamide Followed by Paclitaxel With Paclitaxel Plus Carboplatin as Adjuvant Therapy for Triple-negative Breast Cancer With Homologous Recombination Repair Deficiency
-
CLINICAL_TRIALS study record update · 2019-02-01A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
-
CLINICAL_TRIALS study record update · 2019-01-10Nanoparticle Albumin-Bound Paclitaxel Followed by Dose-Intensive Epirubicin in Combination With Cyclophosphamide as Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2018-10-05An International, Multicenter, Phase II, Randomized, Parallel-arm Trial Investigating the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment
-
CLINICAL_TRIALS study record update · 2018-10-01A Phase IB Trial With OTX015/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2018-08-28An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female Subjects With Locally Recurrent or Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane
-
CLINICAL_TRIALS study record update · 2018-05-31Triple-negative Breast Cancer: a New Perspective on Predictive and Prognostic Biomarkers
-
CLINICAL_TRIALS study record update · 2018-04-30A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
-
CLINICAL_TRIALS study record update · 2018-03-30A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
-
CLINICAL_TRIALS study record update · 2018-03-21A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2018-03-06Phase I/II Randomised, Double- Blind, Multi-centre Study to Assess the Efficacy of AZD2281 When Given in Combination With Paclitaxel in the 1st or 2nd Line Treatment of Patients With Metastatic Triple Negative Breast Cancer.
-
CLINICAL_TRIALS study record update · 2018-02-27A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors
-
CLINICAL_TRIALS study record update · 2017-12-13Phase I Study of Combined Temsirolimus, Erlotinib and Cisplatin in Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2017-11-28Tianjin Medical University Cancer Institute and Hospital
-
CLINICAL_TRIALS study record update · 2017-09-13An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
-
CLINICAL_TRIALS study record update · 2017-06-27A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
-
CLINICAL_TRIALS study record update · 2017-06-26A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2017-03-09A Phase II Study to Determine the Pathological Complete Response Rate and Immunomodulatory Effects of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2016-09-08A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers
-
CLINICAL_TRIALS study record update · 2016-08-08ClinicalTrials.gov study NCT02639832
-
CLINICAL_TRIALS study record update · 2016-04-15An Open Label, Phase II Trial of Afatinib With Paclitaxel for the Neoadjuvant Treatment of Triple-Negative Breast Cancer and Research of Biomarkers of Activity and Efficacy of Afatinib
-
CLINICAL_TRIALS study record update · 2016-03-17ClinicalTrials.gov study NCT00813956
-
CLINICAL_TRIALS study record update · 2016-02-22A Phase II Randomized Multicenter Open Label Prospective Study of Neoadjuvant Chemotherapy Docetaxel With or Without MEK Inhibitor SELUMETINIB in Patients With Early and Locally Advanced Triple Negative Breast Cancer